Results 161 to 170 of about 158,259 (287)

Immune Metabolism of IL-4-Activated B Cells and Th2 Cells in the Context of Allergic Diseases. [PDF]

Front Immunol, 2021
Lin YJ, Goretzki A, Schülke S.
europepmc   +1 more source

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

BMEMat, EarlyView.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan, Qiujie Fang, Cao Fei, Ziyuan Wang, Zhaowei Chen, Guojun Chen, Zhiming Xu, Shu Xu, Zhitong Chen   +8 more
wiley   +1 more source

Corrigendum to "Lung-resident memory Th2 cells regulate pulmonary cryptococcosis by inducing type-II granuloma formation" [Mucosal Immunol. 18(3) (2025) 631-642]. [PDF]

Mucosal Immunol
Ueno K, Nagamori A, Honkyu NO, Kwon-Chung KJ, Miyazaki Y.   +4 more
europepmc   +1 more source

Aberrant expressions of circulating lncRNA NEAT1 and microRNA-125a are linked with Th2 cells and symptom severity in pediatric allergic rhinitis. [PDF]

J Clin Lab Anal, 2022
Wu X, Zhao S, Huang W, Huang L, Huang M, Luo X, Chang S.   +6 more
europepmc   +1 more source

Bcl11b, a novel GATA3-interacting protein, suppresses Th1 while limiting Th2 cell differentiation [PDF]

, 2018
Difeng Fang, Kairong Cui, Gangqing Hu, Rama Krishna Gurram, Chao Zhong, Andrew J. Oler, Ryoji Yagi, Ming Zhao, Suveena Sharma, Pentao Liu, Bing Sun, Keji Zhao, Jinfang Zhu   +12 more
openalex   +1 more source

Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Verekitug, a novel, high‐affinity, fully human monoclonal antibody targeting thymic stromal lymphopoietin receptor (TSLPR), is in development as a potential treatment for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
Dave Singh, Chaim M. Brickman, Peter Lloyd, Ashish Kalra, Subhabrata Biswas, Arkadeep Sinha, Alex Mulvanny, Sumathi Sivapalasingam, Oren M. Becker, Aaron Deykin   +9 more
wiley   +1 more source

Metabolic adaptations of ILC2 and Th2 cells in type 2 immunity. [PDF]

Curr Opin Immunol
Kania AK, Kokkinou E, Pearce E, Pearce E.   +3 more
europepmc   +1 more source

Identification of a novel enhancer essential for Satb1 expression in T_H2 cells and activated ILC2s. [PDF]

Life Sci Alliance, 2023
Nomura A, Kobayashi T, Seo W, Ohno-Oishi M, Kakugawa K, Muroi S, Yoshida H, Endo TA, Moro K, Taniuchi I.   +9 more
europepmc   +1 more source

RORγt‐APCs: The New Masters of Oral Tolerance

Barrier Immunity, EarlyView.
ABSTRACT Oral tolerance is defined by the hypo‐responsiveness of our body to fed antigens, and its failure can lead to immune‐mediated diseases, such as allergy, chronic inflammation and autoimmune diseases. Decades of research have demonstrated that antigen‐presenting cells (APCs) promote oral tolerance by inducing regulatory T cells (Tregs) and/or ...
Thierry Gauthier, WanJun Chen
wiley   +1 more source

Single-cell and chromatin accessibility profiling reveals regulatory programs of pathogenic Th2 cells in allergic asthma. [PDF]

Nat Commun
Khan M, Alteneder M, Reiter W, Krausgruber T, Dobnikar L, Madern M, Waldherr M, Bock C, Hartl M, Ellmeier W, Henriksson J, Boucheron N.   +11 more
europepmc   +1 more source